Literature DB >> 12209315

Analysis of conserved and non-conserved amino acids critical for ALSV (Avian leukemia and sarcoma viruses) integrase functions in vitro.

K Moreau1, C Faure, G Verdier, C Ronfort.   

Abstract

Retroviral integrase (IN) is the viral enzyme responsible for the integration of viral DNA into host cellular DNA. In vitro, recombinant IN protein is able to catalyze the 3'-processing, strand transfer and disintegration activities. In order to analyze the importance of specific residues of ALSV (Avian leukemia and sarcoma viruses) IN protein, we introduced 31 amino acid substitutions either in residues previously shown by others to be involved in IN oligomerization or in selected conserved and non-conserved residues through the IN sequence. We tested, in vitro, the three catalytic activities of these mutants as well as their capacity to bind DNA. We found that (i) 88% of the substitutions occurring on well-conserved residues have an effect on IN activities (ii) two mutants (S85T in the central catalytic domain and N197C in the C-terminal domain) present a reduced efficiency of DNA binding compared to the wild type protein. Moreover, all mutations made on the dimer interface of C-terminal domain present reduced activities, suggesting an important role of this part of the protein. Finally, for some mutations, we observed differences between the ALSV and HIV (Human immunodeficiency virus) IN corresponding residues.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12209315     DOI: 10.1007/s00705-002-0831-5

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  8 in total

1.  A substitution in rous sarcoma virus integrase that separates its two biologically relevant enzymatic activities.

Authors:  Wesley M Konsavage; Stephen Burkholder; Malgorzata Sudol; Amy L Harper; Michael Katzman
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Recombinant human immunodeficiency virus type 1 integrase exhibits a capacity for full-site integration in vitro that is comparable to that of purified preintegration complexes from virus-infected cells.

Authors:  Sapna Sinha; Duane P Grandgenett
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

3.  Transcriptional coactivator LEDGF/p75 modulates human immunodeficiency virus type 1 integrase-mediated concerted integration.

Authors:  Krishan K Pandey; Sapna Sinha; Duane P Grandgenett
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

4.  Inhibition of human immunodeficiency virus type 1 concerted integration by strand transfer inhibitors which recognize a transient structural intermediate.

Authors:  Krishan K Pandey; Sibes Bera; Jacob Zahm; Ajaykumar Vora; Kara Stillmock; Daria Hazuda; Duane P Grandgenett
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

5.  Molecular and genetic determinants of rous sarcoma virus integrase for concerted DNA integration.

Authors:  Roger Chiu; Duane P Grandgenett
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

6.  Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance.

Authors:  Jacob A Zahm; Sibes Bera; Krishan K Pandey; Ajaykumar Vora; Kara Stillmock; Daria Hazuda; Duane P Grandgenett
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

7.  Cross-packaging of human immunodeficiency virus type 1 vector RNA by spleen necrosis virus proteins: construction of a new generation of spleen necrosis virus-derived retroviral vectors.

Authors:  Zahida Parveen; Muhammad Mukhtar; Adrienne Goodrich; Edward Acheampong; Ralph Dornburg; Roger J Pomerantz
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

8.  A crystal structure of the catalytic core domain of an avian sarcoma and leukemia virus integrase suggests an alternate dimeric assembly.

Authors:  Allison Ballandras; Karen Moreau; Xavier Robert; Marie-Pierre Confort; Romain Merceron; Richard Haser; Corinne Ronfort; Patrice Gouet
Journal:  PLoS One       Date:  2011-08-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.